MA29570B1 - Procede pour le traitement des tumeurs du cerveau a l'aide d'anticorps - Google Patents

Procede pour le traitement des tumeurs du cerveau a l'aide d'anticorps

Info

Publication number
MA29570B1
MA29570B1 MA30523A MA30523A MA29570B1 MA 29570 B1 MA29570 B1 MA 29570B1 MA 30523 A MA30523 A MA 30523A MA 30523 A MA30523 A MA 30523A MA 29570 B1 MA29570 B1 MA 29570B1
Authority
MA
Morocco
Prior art keywords
brain tumors
antibodies
treatment
patient
monoclonal antibody
Prior art date
Application number
MA30523A
Other languages
English (en)
Inventor
Kyung Jin Kim
John Laterra
Bachchu Lal
Original Assignee
Kennedy Krieger Inst Inc
Galaxy Biotech Llc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Krieger Inst Inc, Galaxy Biotech Llc, Univ Johns Hopkins filed Critical Kennedy Krieger Inst Inc
Publication of MA29570B1 publication Critical patent/MA29570B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur une méthode de traitement des tumeurs du cerveau d'un patient par administration systémique d'un anticorps monoclonal.
MA30523A 2005-06-02 2007-12-27 Procede pour le traitement des tumeurs du cerveau a l'aide d'anticorps MA29570B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68711805P 2005-06-02 2005-06-02
US75109205P 2005-12-15 2005-12-15

Publications (1)

Publication Number Publication Date
MA29570B1 true MA29570B1 (fr) 2008-06-02

Family

ID=37482322

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30523A MA29570B1 (fr) 2005-06-02 2007-12-27 Procede pour le traitement des tumeurs du cerveau a l'aide d'anticorps

Country Status (14)

Country Link
US (2) US20070036797A1 (fr)
EP (1) EP1885400A4 (fr)
JP (2) JP2008545753A (fr)
KR (1) KR20080026562A (fr)
AU (1) AU2006252419B2 (fr)
BR (1) BRPI0611009A2 (fr)
CA (1) CA2607699A1 (fr)
CR (1) CR9512A (fr)
IL (1) IL187318A0 (fr)
MA (1) MA29570B1 (fr)
MX (1) MX2007015056A (fr)
NO (1) NO20080012L (fr)
RU (1) RU2007146986A (fr)
WO (1) WO2006130773A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
KR20080056167A (ko) 2005-09-26 2008-06-20 메다렉스, 인코포레이티드 씨디70에 대한 인간 모노크로날 항체
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
ES2378097T3 (es) * 2006-06-02 2012-04-04 Aveo Pharmaceuticals, Inc. Proteínas de unión al factor de crecimiento de hepatocitos (HGF)
ATE495195T1 (de) 2006-06-02 2011-01-15 Aveo Pharmaceuticals Inc Hepatocytenwachstumsfaktor-(hgf-)bindungsprotei e
CA2664738C (fr) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions et procedes permettant de diagnostiquer et de traiter le cancer
JP2010513306A (ja) * 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Ｃｄ７０に結合するヒト抗体およびその使用
MX2010002116A (es) * 2007-08-24 2010-03-26 Novartis Ag Un modulador de nrg1 para el tratamiento de trastornos respiratorios.
WO2009126840A1 (fr) * 2008-04-11 2009-10-15 Galaxy Biotech, Llc Combinaison d’un inhibiteur d’hgf et d’un inhibiteur d’hedgehog pour le traitement du cancer
PE20091714A1 (es) * 2008-04-11 2009-11-15 Galaxy Biotech Llc Combinacion del inhibidor hgf y el agonista pten
CA2725873C (fr) * 2008-05-29 2018-05-01 Galaxy Biotech, Llc Anticorps monoclonaux diriges contre un facteur de croissance fibroblastique basique
WO2010119991A2 (fr) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Nouveau procédé de traitement anticancéreux
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
MX2012008958A (es) * 2010-02-18 2012-08-23 Genentech Inc Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
RU2439160C1 (ru) * 2010-06-25 2012-01-10 Государственное общеобразовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ получения моноклональных антител к аблюминальному мембранному антигену церебральных эндотелиоцитов
EP2588107A1 (fr) * 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited Combinaison d'un inhibiteur de cmet et d'un anticorps dirigé contre hgf et/ou cmet
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
JP6170496B2 (ja) 2011-09-23 2017-07-26 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
WO2016070051A2 (fr) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Thérapie combinée pour le traitement d'une maladie
EP3353204B1 (fr) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Anticorps anti-vegf/dll4 bi-spécifique pour le traitement du cancer de l'ovaire résistant au platine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
MXPA06000508A (es) * 2003-07-18 2006-04-05 Amgen Inc Agentes de union especifica al factor del crecimiento de los hepatocitos.
EP2392565B1 (fr) * 2003-09-26 2014-03-19 Exelixis, Inc. Modulateurs de c-Met et procédés d'utilisation
JP5368701B2 (ja) * 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
US7964365B2 (en) * 2005-11-08 2011-06-21 The United States of Americam as represented by the Secretary, Department of Health and Human Services Methods for diagnosing and monitoring the progression of cancer
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
WO2009126840A1 (fr) * 2008-04-11 2009-10-15 Galaxy Biotech, Llc Combinaison d’un inhibiteur d’hgf et d’un inhibiteur d’hedgehog pour le traitement du cancer
TW201002346A (en) * 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer

Also Published As

Publication number Publication date
JP2013136580A (ja) 2013-07-11
CR9512A (es) 2008-04-16
US20100221250A1 (en) 2010-09-02
AU2006252419A1 (en) 2006-12-07
CA2607699A1 (fr) 2006-12-07
BRPI0611009A2 (pt) 2010-08-10
WO2006130773A3 (fr) 2009-04-16
EP1885400A2 (fr) 2008-02-13
MX2007015056A (es) 2008-03-11
NO20080012L (no) 2008-02-20
WO2006130773A2 (fr) 2006-12-07
RU2007146986A (ru) 2009-06-27
IL187318A0 (en) 2008-04-13
JP2008545753A (ja) 2008-12-18
US20070036797A1 (en) 2007-02-15
EP1885400A4 (fr) 2011-01-26
KR20080026562A (ko) 2008-03-25
AU2006252419B2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
MA29570B1 (fr) Procede pour le traitement des tumeurs du cerveau a l'aide d'anticorps
PH12018500062A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
MA30337B1 (fr) Anticorps
LUC00053I9 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
TN2018000419A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof.
MA29595B1 (fr) Anticorps anti-cd40 humanises et procedes d'utilisation
MA51669B1 (fr) Modulateurs de tmem16a
CR7922A (es) Inmunizacion activa para generar anticuerpos para beta-a- soluble
DE60042693D1 (de) Dosierung für die behandlung mit anti erbb2-antikörpern
HUP0302589A2 (hu) A béta-amiloid peptidet felismerő humanizált ellenanyagok
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
MA31886B1 (fr) Anticorps anti-hepcidine et utilisations de ceux-ci
PH12021552334A1 (en) Antibodies to pyroglutamate amyloid-㟠and uses thereof
DE60226051D1 (de) Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren
MA53765A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA38161A1 (fr) Anticorps anti-bmp-6
MA58646A1 (fr) Tubulysines et conjugués tubulysines-protéines
MA37670A1 (fr) Anticorps anti-transglutaminase 2
MA35173B1 (fr) Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
MA49607A1 (fr) Anticorps monoclonal pour il-5ra
MA53186A1 (fr) Anticorps monoclonal qui se lie spécifiquement à cd20
MA31757B1 (fr) Traitement de symptomes vasomoteurs
MA56998B1 (fr) Traitement de symptômes induits par le cycle menstruel
EP4340881A4 (fr) Anticorps pour le traitement d'alpha-synucléinopathies